455-36-7

Applied Filters:

Keyword:'455-36-7'

Showing 1-30 of 80 results for "455-36-7" within Technical Documents

R. Soc. Lond. B. Bio. Sci., 354, 289 (1999). 7. Waterman, S.A., Prog. Neurobiol., 60, 181 (2000). 8. Uneyama, H. et al., Int. J. Mol. Med., 3, 455 (1999). 9. Ophoff, R.A. et al., Trends Pharmacol

Product Information Sheet - GALF

enhance the fluorescence of the 4-MU. The 4-MU can be excited at 365 nm; it’s emission maximum is at 455 nm. E. coli β-galactosidase serves as a positive control enzyme. This kit includes all buffers

Product Information Sheet - T4376

Biochem., 35, 2437 (1996). 13. Shaw, E., Cold Spring Harbor Conferences on Cell Proliferation, 2, 455 (1975). 14. Powers, J.C. and Harper, J.W., "Inhibitors of Serine Proteases" in Proteinase Inhibitors

Anti-Calcium Channel (b3 Subunit) (Cacnb3l) antibody produced in rabbit (C1978)

Soc. Lond. B. Biol. Sci., 354, 289 (1999). 7. Waterman, S.A., Prog. Neurobiol., 60, 181 (2000). 8. Uneyama, H. et al., Int. J. Mol. Med., 3, 455 (1999). 9. Ophoff, R.A. et

Anti-Calcium Channel (Cardiac alpha1C Subunit) (L-type of Voltage-gated Ca2+ Channel) (C4980)

R. Soc. Lond. B. Bio. Sci., 354, 289 (1999). 7. Waterman, S.A., Prog. Neurobiol., 60, 181 (2000). 8. Uneyama, H. et al., Int. J. Mol. Med., 3, 455 (1999). 9. Ophoff, R.A. et al., Trends Pharmacol.

Developed in Rabbit Affinity Isolated AntibodyAnti-cdk-1 (p34cdc2)

. Soc. Lond. B. Bio. Sci., 354, 289 (1999). 7. Waterman, S.A., Prog. Neurobiol., 60, 181 (2000). 8. Uneyama, H., et al., Int. J. Mol. Med., 3, 455 (1999). 9. Ophoff, R.A., et al., Trends Pharmacol

Product Information Sheet - GUSA

enhance the fluorescence of the 4-MU. The 4-MU can be excited at 365 nm; it’s emission maximum is at 455 nm. E. coli β-glucuronidase serves as a positive control enzyme. This kit includes all buffers

Data Sheet - T2692

RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun., 256, 449-455 (1999). 10. Nakagawa, N., et al., RANK is the essential signaling receptor for osteoclast differentiation

Investigation of Various Polymers for SLS 3D-Printing of Solid Oral Dosage Forms

fully submerged in powder post-printing, collected via sieving, and dedusted). • 2.3 W diode (λ=455 nm) laser used. Characterization • XRD, DSC, friability, mass and size analysis, HPLC, dissolution

Anti-Calcium Channel (alpha1A Subunit) (P/Q-Type of Voltage-Gated Ca2+ Channel) (C1353)

1995). 7. Seagar, M. et al., Philos. Trans. R.. Soc. Lond. B. Biol. Sci., 354, 289 (1999). 8. Waterman, S. A., Prog. Neurobiol., 60, 181 (2000). 9. Uneyama, H. et al., Int. J. Mol. Med., 3, 455

Parteck® LM Excipient System Reduce complexity in your formulation and optimize results

0.414 0.830 Mg-Stearate 455:1 10C No 0.500 0.502 0.012 2.482 Yes 0.500 0.498 0.009 1.906 M as s flo w [ kg /h ] Time [s] Parteck® LM

Anti-Calcium Channel ( 1B Subunit)

(2000). 7. Uneyama, H. et al., Int. J. Mol. Med., 3, 455 (1999). 8. Ophoff, R. A. et al., Trends Pharmacol. Sci., 19, 121 (1998). 9. Burgess, D. L. and Noebels, J.L., Epilepsy Res.,36, 111 (

ANTI-CALCIUM CHANNEL (a1E Subunit)

al., Int. J. Mol. Med., 3, 455 (1999). 11. Ophoff, R.A. et al., Trends Pharmacol. Sci., 19, 121 (1998). 12. Burgess, D.L. and Noebels, J.L., Epilepsy Res., 36, 111 (1999).

Anti-Calcium Channel (alpha1 Subunit) Pan (C1103)

al., Int. J. Mol. Med., 3, 455 (1999). 12. Ophoff, R. A. et al., Trends Pharmacol. Sci., 19, 121 (1998). 13. Burgess, D. L. and Noebels, J.L., Epilepsy Res., 36, 111 (1999). 14. Foster

Anti-Calcium Channel (a1C Subunit) (L-type of Voltage-gated Ca2+ Channel) antibody produced in rabbit (C1603)

Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review)., Int. J. Mol. Med., 3, 455-66 (1999). 11. Ophoff, R.A. et al., P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy

Anti-Calcium Channel (a1D Subunit) (L-type of Voltage-gated Ca2+ Channel) antibody produced in rabbit (C1728)

Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review)., Int. J. Mol. Med., 3, 455-66 (1999). 10. Ophoff, R.A. et al., P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy

Data Sheet - H107

Sulpride (S-116) 38 Testosterone 0.03 30 1154 Tetrahydrocannabinol (T-119,120) 455 Veratridine (V-109) 2.0 >2 Vitamin A 0.01 5.0 500 Vitamin D 35 *Solubility

XP725 Antibody Number-Lot Number 071M4826

e-f g-h 1.1 1 2 3 4 25 26 27 28 49 50 51 52 73 74 75 76 1.2 5 6 7 8 29 30 31 32 53 54 55 56 77 78 79 80 1.3 9 10 11 12

Product Information Sheet - C0926

38 Testosterone T 1500 0.03 30 1154 Tetrahydrocannabinol T 119 T 120 455 Veratridine V 5754 2.0 >2 Vitamin A R 7632 0.01 5.0 500 Vitamin D E 5750

GOAT ANTI-CHOLINE ACETYLTRANSFERASE (ChAT) AFFINITY PURIFIED POLYCLONAL ANTIBODY

REFERENCES: 1. Brain Research Bulletin (1987) 8:447-455. 2. Sleep (1988) 11:1-16. 3.

New MSDS (according to GHS)

irreversiblen Schadens durch Einatmen, Berührung mit der Haut und durch Verschlucken. S-Sätze 7-16-36/37-45 Behälter dicht geschlossen halten. Von Zündquellen fernhalten - Nicht rauchen. Bei der Arbeit

100MG PHR2283-100MG 707-37-9 707-36-8 941-37-7 351329-88-9 356572-08-2 33103-93-4 15210-60-3 80121-67-1 119478-56-7 1053703-36-8 89-57-6 591-27-5 95-55-6 19767

Applicaton Note: A new MILLIPLEX® map multiplex panel enhances simultaneous quantitation of metabolic hormones in human serum and plasma

antisera and cause a spuriously high plasma immunoreactive glucagon level. Endocr J. 1995 Aug;42(4):455-60. 11. Teixeira RC, Nico MM, Ghideti AC. Necrolytic migratory erythema associated with glucagonoma

User Guide - 1.73026 - Color Manual - English